Table 1.

Characteristics of the study population and infection severity

Patient ID	Disease group	Age (years)	Spike+ B cells sequenced	RBD+ B cells sequenced	Gender	Days post symptom onset		Spike+ Bcell frequency (/105 B cells)		RBD+ Bcell frequency (/105 B cells)
						t1	t2	t1	t2	t1	t2
2850955	Uninfected control	26	n/a	n/a	Male
2584766	Uninfected control	44	n/a	n/a	Female
250011 a	Mild	63	105	76	Female	68	181	224	41	47	71
250017 b	Mild	78		105	Male	73	138	60	85	71	175
213021 f	Mild	52		51	Male	81	147	28.2	62	7.1	33
213007 g	Moderate	34	0	146	Male	67	132	202	133	418	44
289036 c	Severe	84	0	133	Female	87	156	53	67	142	138
247004 d	Severe	23	0	143	Male	58	116	155	106	329	355
250002 e	Severe	72	43	121	Male	49	110	40	48	38	64

BD, two times a day; n/a, not available; PRN, pro re nata (as needed); QID, four times a day; RBD, receptor‐binding domain.

^a Had obesity and no treatments. SpO₂ of 98%.

^b Had hypertension and was a smoker. SpO₂ not calculated.

^c Telmisartan 80 mg mane; amlodipine 5 mg mane; sitagliptin 100 mg mane; allopurinol 1 tablet every 2 days; Movicol 2 sachets BD PRN for constipation; paracetamol 1 g QID PRN for fever. Had hypertension, diabetes and obesity. Optimal oxygen saturation (SpO₂) of 71.7%.

^d Penrindopril, amlondopril, clotrimazole, prednisone, benzylpenicillin–ceftriaxone–doxycycline, rosuvastatin. Chronic lung disease (asthma). Smoker. SpO₂ of 92%.

^e Ibuprofen prior to admission. Inpatient: paracetamol, nebulized saline. SpO₂ of 91%.

^f No comorbidity or documented treatment. SpO₂ not calculated.

^g SpO₂ of 99%.